BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 84 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18 | -97.3% | 7,656 | -92.4% | 0.00% | – |
| Q2 2023 | $671 | -35.8% | 100,720 | +79.8% | 0.00% | – |
| Q1 2023 | $1,045 | +841.4% | 56,023 | +990.8% | 0.00% | – |
| Q4 2022 | $111 | -98.9% | 5,136 | +533.3% | 0.00% | – |
| Q3 2022 | $10,000 | -68.8% | 811 | -66.7% | 0.00% | – |
| Q2 2022 | $32,000 | -47.5% | 2,437 | -15.6% | 0.00% | – |
| Q1 2022 | $61,000 | -92.8% | 2,889 | -93.1% | 0.00% | – |
| Q4 2021 | $852,000 | +171.3% | 41,858 | +304.8% | 0.00% | – |
| Q3 2021 | $314,000 | +82.6% | 10,341 | +74.9% | 0.00% | – |
| Q2 2021 | $172,000 | +681.8% | 5,912 | +1131.7% | 0.00% | – |
| Q4 2020 | $22,000 | -98.2% | 480 | -98.3% | 0.00% | -100.0% |
| Q3 2020 | $1,235,000 | +3759.4% | 28,487 | +4647.8% | 0.00% | – |
| Q2 2020 | $32,000 | -68.3% | 600 | -91.4% | 0.00% | – |
| Q4 2019 | $101,000 | +381.0% | 6,940 | +133.5% | 0.00% | – |
| Q3 2019 | $21,000 | -51.2% | 2,972 | -23.5% | 0.00% | – |
| Q2 2019 | $43,000 | -99.3% | 3,886 | -99.4% | 0.00% | -100.0% |
| Q1 2018 | $6,331,000 | – | 618,249 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 60,000 | $151,800 | 0.16% |
| XTX Topco Ltd | 33,605 | $85,021 | 0.02% |
| Beacon Pointe Advisors, LLC | 301,735 | $763,390 | 0.01% |
| AllSquare Wealth Management LLC | 4,527 | $11,453 | 0.01% |
| Virtus ETF Advisers LLC | 4,646 | $11,754 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 27,553 | $69,709 | 0.01% |
| SeaCrest Wealth Management, LLC | 16,550 | $41,872 | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 33,940 | $85,868 | 0.01% |
| Cutler Group LLC / CA | 4,000 | $50 | 0.01% |
| Capital Investment Advisory Services, LLC | 17,991 | $45,517 | 0.00% |